Description
AZD-5363 is an oral pan-AKT inhibitor that causes hyperphosphorylation of AKT, locking it in a catalytically inactive state, unable to phosphorylate downstream signaling substrates such as PRAS40 and GSK-β. This compound displays anticancer chemotherapeutic activity, inhibiting proliferation and inducing tumor regression in in vitro and in vivo models of HER2+ breast cancer and prostate cancer. AZD-5363 may also exhibit inhibitory activity against Rho-associated protein kinase (ROCK), p70S6K, PKA, MKK1, MSK1, MSK2, PKC, PKG, PRKX, and RSK2/3.